Needham named Mind Medicine (MNMD) a top pick for 2026 and added the stock to its Conviction List. The firm keeps a Buy rating on the shares with a $28 price target Mind has a “catalyst-rich” 2026 with three pivotal readouts, the analyst tells investors in a research note. Needham sees the readouts making 2026 a “transformative year” for the company. Mind’s MM120 is “de-risked” in generalized anxiety disorder based on the “robust” Phase 2b data, the firm contends.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD:
- Ametek, MindMed, Atai, Prime and KB Home Trending
- MindMed Expands Into Autism: What Investors Should Know About the New MM402 Trial
- Midday Fly By: Wegovy weight loss pill approved, ServiceNow inks security deal
- Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
- Video: HII sails higher as President unveils plans for ‘Trump-class’ battleships